top
Search terms
Results 1 - 8 of 8 - ordered by :
Ehjournal

The authors critically evaluate the clinical implications of the use of non-fasting rather than fasting lipid profiles, and provide guidance for laboratory reporting of abnormal non-fasting or ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/07/2016 Item size : 205989 bytes
Ehjournal

In his notes he wrote: I found no material disease of the heart, except that the coronary arteries were thickened2 Rudolf Virchow was the first to recognize the inflammatory nature of atherosclerosis ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/03/2015 Item size : 221872 bytes
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Guidelines for the primary prevention of cardiovascular disease (CVD) with statins, including the most recent,1 fail to make optimal ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 14/11/2015
Ehjournal

Download the Issue @ a Glance podcast Subscribe to the EHJ Podcast Elevated levels of LDL-cholesterol are determined mainly genetically1 and are the most important risk factor for atherosclerosis in ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 01/05/2016
Ehjournal

Furthermore, the EMPA-REG OUTCOME trial using the novel antihyperglycaemic agent, empagliflozin,8 a selective sodiumglucose co- transporter inhibitor, significantly reduced cardiovascular mortality; ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 07/02/2016
Ehjournal

LipidsPCSK9Acute coronary syndromesCohort studiesFamilial hypercholesterolaemiaIntroduction Proprotein convertase subtilisin kexin 9 (PCSK9) has received considerable attention in the last decade as ...

European Heart Journal, FASTTRACK CLINICAL RESEARCH, Baris Gencer, Fabrizio Montecucco, David Nanchen, Federico Carbone, Roland Klingenberg, Nicolas Vuilleumier, Soheila Aghlmandi, Dik Heg, Lorenz ...

Date : 07/02/2016
Ehjournal

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs able to decrease LDL-C by 5070% when administered either as a monotherapy or on a background with statins.46 ...

European Heart Journal, ISSUE @ A GLANCE, Thomas F. Lüscher

Date : 21/09/2015
Ehjournal

Based on personal and familial history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clinical FH were used: the Dutch Lipid Clinic Network ...

European Heart Journal, CLINICAL RESEARCH, David Nanchen, Baris Gencer, Reto Auer, Lorenz Räber, Giulio G. Stefanini, Roland Klingenberg, Christian M. Schmied, Jacques Cornuz, Olivier Muller, ...

Date : 21/09/2015